Jianpeng Guo, Wenying Yu, Guiping Cai, Wenda Zhang, Shanshan Li, Jiawen Zhu, Dongmei Song, Lingyi Kong
文献索引:10.1016/j.ejmech.2018.03.053
全文:HTML全文
Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers. Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis. However, the discovery of selective STAT3 inhibitors is still challenging to date. In this study, a series of small-molecular (MW < 500) benzensulfanilamide derivatives were designed to selectively suppress STAT3 activation for anti-cancer treatment. The most potent compound 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor. Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation. In addition, 11 elevated the ROS level and induced apoptosis of cancer cells. Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.
New lipophilic isoniazid derivatives and their 1,3,4-oxadiaz...
2018-04-10 [10.1016/j.ejmech.2018.04.017] |
2-Benzylpiperazine: A new scaffold for potent human carbonic...
2018-04-03 [10.1016/j.ejmech.2018.04.002] |
Anti-leishmanial click modifiable thiosemicarbazones: Design...
2018-04-03 [10.1016/j.ejmech.2018.04.003] |
Design and synthesis of BPR1K653 derivatives targeting the b...
2018-04-03 [10.1016/j.ejmech.2018.03.064] |
Discovery of potent and selective BRD4 inhibitors capable of...
2018-04-03 [10.1016/j.ejmech.2018.04.006] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved